Baxter (NYSE:BAX) Rating Upgrade
In a research report made public on Wednesday, 3 January, Raymond James increased shares of Baxter (NYSE:BAX) to Outperform rating from Mkt Perform rating.
According to data compiled by Thomson Reuters, Baxter (NYSE:BAX)’s stock is covered by 11 equity analysts across the Street, with 1 analysts giving it a Sell rating, 3 a Buy rating, while 11 consider it a Hold. The 12-month consensus target price for the stock is $48.82, which reflects an downside potential of 20.63% over the current price.
Third Point Llc had the largest stake with ownership of 51.90M shares as of Q2 2015 for 21.48% of the stock exposure. Sector Gamma As is another quite bullish fund who is possessing 1.08M shares of Baxter or 9.63% of their stock exposure. In addition, Veritas Asset Management Llp have 5.01% of their stock exposure invested in the company for 9.29M shares. The New York-based fund 13D Management Llc revealed it had purchased a stake worth about 3.9% of the fund’s stock portfolio in Baxter. The California-based fund Aristotle Capital Management Llc is also positive about the stock, possessing 196,743 shares or 3.27% of their stock exposure.
Baxter (NYSE:BAX) Profile
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Baxter (NYSE:BAX) closed at $61.51 yesterday. A total of 2.39M shares of the company’s stock traded hands. This is down from average of 2.45M shares. Baxter has a 52 week low of $43.13 and a 52 week high of $63.14. The company has a market cap of $33.52B and a P/E ratio of 37.52.
Get the latest Baxter (NYSE:BAX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Baxter (NYSE:BAX) Given The Better Outperform Rating by Raymond James. No Longer Has Mkt Perform Rating appeared first on Octafinance.